Aman's Global Market Intelligence

1 · Executive dashboard

Neutral / event-risk

Regime call: cautiously constructive tape, but not clean risk-on. U.S. tech futures and Europe were positive while gold was sharply bid, Treasury yields remained high, and the market awaited a binary labor release. The oil/Hormuz channel remains the dominant inflation and geopolitical risk.

S&P 500 · Aug 6 close7,709.96−0.18%

Nasdaq Composite26,348.35−0.06%

Dow Jones53,885.10−0.85%

Russell 20003,001.55−0.58%

VIX15.26+0.73%

U.S. 2Y · Aug 64.25%+7 bp d/d

U.S. 10Y · Aug 64.69%+6 bp d/d

Dollar proxyEUR/USD 1.1529DXY unavailable

WTI Sep · ~07:51 ET$76.85−0.6%

Gold Dec · intraday high$4,380.20+6.6% week pace

Region / instrument	Level	Move	Session / timestamp
Nikkei 225	65,606.71	−0.12%	Completed Asia session
Hang Seng	25,668.03	+0.54%	Completed Asia session
Shanghai Composite	3,940.04	+1.02%	Completed Asia session
CSI 300	—	+0.93%	Completed Asia session
Kospi	6,258.77	−0.60%	Completed Asia session
Euro Stoxx 50	6,546.26	+0.67%	07:46 ET early trade
DAX	26,370.28	+0.88%	08:01 ET early trade
FTSE 100	10,954.20	+1.04%	08:01 ET early trade
S&P 500 future	7,754.50	+0.26%	07:51 ET
Nasdaq 100 future	29,654.75	+0.56%	07:51 ET
Dow future	54,089	+0.14%	07:51 ET

1 · Jobs report at 14:30 CEST

Consensus cited by CNBC: +83,000 payrolls, unemployment unchanged at 4.2%. No pre-release trade has a strong edge because rates, dollar and growth equities can reprice together.

2 · Oil/Hormuz risk persists

Oil eased premarket after Thursday's jump, but negotiations and traffic restrictions remain unstable. This is the main upside-inflation / downside-duration risk.

3 · Tech breadth improves

Nasdaq futures led; CNBC reported SOXX up more than 5% on the week. Cloudflare gained about 16% premarket after guidance, confirming selective reward for execution.

2 · Market-moving analysis

Facts separated from inference

Confirmed

Aug. 6 official Treasury par closes: 2Y 4.25%, 10Y 4.69%, versus 4.18% and 4.63% on Aug. 5.
Thursday's S&P decline was shallow; energy and technology were the only positive sectors late in the session, while Dow weakness included Salesforce's leadership-shuffle reaction.
WTI settled Thursday at $77.29 and Brent at $82.49 after draft restrictions affecting U.S./Israeli shipping through Hormuz were reported.
Cloudflare rose roughly 16% and Airbnb 7% premarket after results/outlook; these are verified headline moves, not standalone recommendations.
BLS scheduled July employment at 08:30 ET today; data were not yet public at cutoff.

Inference / decision use

Rates are the gatekeeper: a hot wage/payroll print would likely pressure long-duration AI and pre-profit quantum names more than cash-generative platforms.
Gold + equity futures up is not pure risk-on; it suggests hedging demand alongside growth optimism.
Rotation is selective: strong AI infrastructure earnings can work, but memory/storage names showed that high expectations plus softer guidance can trigger double-digit drawdowns.
Geopolitical convexity: an enforceable Hormuz reopening would help cyclicals and duration; renewed disruption would favor energy/defensives and hurt rate-sensitive speculation.

3 · Thematic dashboards

AI stack Leadership intact

Leaders: semiconductors recovered this week; NVDA closed $218.99 on Aug. 6. Its last reported quarter delivered $81.6B revenue, +85% y/y.
Catalyst: NVIDIA Q2 FY27 results are company-confirmed for Aug. 26 at 2:00 PT; Marvell's IR calendar lists Aug. 27.
Demand evidence: Broadcom reported Q2 AI semiconductor revenue of $10.8B, +143% y/y, and guided Q3 AI semiconductor revenue to $16B.
Laggard/risk: guidance sensitivity is acute—Western Digital fell 13% and Sandisk more than 6% after results/guidance.
Risk: concentration, capex digestion, export controls, power availability and 4.69% 10Y yields.

Quantum Commercial proof vs burn

IONQ: Q2 revenue $80.1M, +287% y/y; raised 2026 revenue outlook to $280–290M. But adjusted EBITDA loss was $120.3M and pro-forma liquidity after SkyWater was $2.0B.
RGTI: Q2 revenue $5.1M against $28.1M operating loss; cash/investments $541.3M. Shares closed $16.53.
Technical reality: IONQ closed $39.72 and RGTI remains 25% lower YTD despite a recent bounce.
Risk: valuations remain disconnected from current operating profit; technical roadmaps, government awards and acquisition benefits are execution-dependent.

Peptide / metabolic biotech Strong demand, binary challengers

LLY: Q2 revenue $22.97B, +48%; Mounjaro $9.94B, +91%; Zepbound $4.93B, +46%. Shares closed $1,191.94.
VKTX: VANQUISH-1/2 Phase 3 fully enrolled; maintenance-dosing data expected Q3; oral VK2735 Phase 3 planned Q4. Cash was $502M.
Regulatory context: FDA's 2026 list confirms 30 novel approvals through Aug. 5; no new peptide-specific approval at cutoff materially changed today's listed setup.
Risk: competition, tolerability, pricing/reimbursement, manufacturing scale and binary clinical outcomes. Viking is pre-revenue and single-franchise concentrated.

4 · Ranked ideas

Conditional, not predictions

#1 NVDA · NVIDIA Bullish / confirmation needed

Nasdaq · approx. $5.3T mega-cap · AI compute/networking · lower liquidity risk, high valuation/event risk

Day trade: no pre-jobs edgeSwing 1–4 weeks: conditionalInvestment 3–12+ months: applicable

Thesis / direction: evidence supports continued AI demand leadership; shares may outperform if rates stabilize and earnings validate growth.

Catalyst: Aug. 26 Q2 FY27 results; sector read-through from networking and hyperscaler capex.

Evidence: Q1 revenue $81.6B, +85% y/y; Aug. 6 close $218.99 on 113.7M shares; semiconductor tape rebounded this week.

Counterargument: $5T+ capitalization embeds exceptional execution; export controls, customer concentration and capex digestion can compress multiples.

Entry / confirmation: wait for post-jobs stabilization; favor a hold above Aug. 6 low $217 or a high-volume breakout above Aug. 6 high $223.63—not a blind open.

Invalidation / downside: decisive close below $217 with rising 10Y yields weakens swing thesis; material guidance deceleration or supply/export shock invalidates investment case. Downside can be sharp toward prior consolidation.

Principal risks: earnings gap, valuation, geopolitics, regulation, power/supply constraints.

Technical/fundamental: near 52-week upper range ($164.07–$236.54); strong fundamental momentum, but price is not cheap.

Confidence

Risk

Opportunity

Confidence: primary financials + liquid price data. Risk: valuation/event concentration. Opportunity: earnings catalyst + sector strength, discounted for macro event.

#2 LLY · Eli Lilly Bullish long-term / do not chase

NYSE · approx. $1.1T mega-cap · peptide/metabolic therapeutics · moderate-high valuation and policy risk

Day trade: no edgeSwing: buy-on-confirmation onlyInvestment 3–12+ months: applicable

Thesis / direction: extraordinary incretin volume growth and raised guidance can support long-term compounding, but volatility near highs argues for patience.

Catalyst: continued Mounjaro/Zepbound supply expansion, pipeline updates and guidance execution.

Evidence: Q2 revenue +48%; Mounjaro +91%; Zepbound +46%; Aug. 6 close $1,191.94.

Counterargument: premium valuation, political pricing pressure, capacity spending and competition from Novo/Viking/next-generation agents.

Entry / confirmation: favor pullback support above roughly $1,174 (Aug. 6 low) or a close above $1,231 (Aug. 6 high) after the macro release.

Invalidation / downside: sustained break below $1,174 plus estimate cuts; demand/safety/reimbursement deterioration invalidates. A valuation reset could be material despite growth.

Principal risks: pricing, manufacturing, safety, patent/litigation, pipeline readouts.

Context: recent range is wide; execution is strong, but position sizing should reflect single-day earnings/clinical gaps.

Confidence

Risk

Opportunity

Confidence: company-reported sales/guidance. Risk: premium multiple + policy. Opportunity: category leadership, reduced for crowded positioning.

#3 RGTI · Rigetti Computing Avoid / bearish bias

Nasdaq · approx. $5.5B small/mid-cap speculative · quantum · high volatility/dilution risk; not an asserted short

Day trade: avoid post-earnings noiseSwing: bearish/avoidInvestment: watch milestones only

Thesis / direction: equity value looks difficult to reconcile with $5.1M quarterly revenue and $28.1M operating loss; relative downside risk remains high if enthusiasm fades.

Catalyst: post-Q2 price discovery; government funding finalization and fidelity roadmap milestones.

Evidence: $16.53 Aug. 6 close; YTD −25.4%; $541.3M liquidity and no debt offer runway, but losses dwarf revenue.

Counterargument: strong cash, potential up-to-$100M Commerce funding, HPE/PSC collaboration and improved system metrics can sustain strategic value.

Entry / confirmation: this is an avoid, not a borrow recommendation. Bearish confirmation would be a break below $16.06; no borrow availability/fee is asserted.

Invalidation / downside: bearish view invalidated by sustained close above $17.14 with volume plus funded commercial awards. For longs, downside includes return toward July lows and dilution.

Principal risks: squeeze risk, borrow uncertainty, binary technical claims, dilution, government-funding conditions.

Liquidity: Aug. 6 volume about 22.5M, but volatility is high (reported beta 2.02) and spreads can widen around news.

Confidence

Risk

Opportunity

Confidence: primary Q2 data + price history. Risk: extreme volatility/squeeze. Opportunity: valuation mismatch, discounted because short implementation is unknown.

#4 IONQ · IonQ Avoid at current evidence

NYSE · approx. $14.8B mid-cap speculative · quantum platform/foundry · high execution and acquisition risk

Day trade: no edgeSwing: avoidInvestment: watch commercial conversion

Thesis / direction: revenue growth is real, but the operating-cost base and valuation require exceptional conversion; risk/reward is not compelling without a better price or margin evidence.

Catalyst: integration updates, 256-qubit/QEC demonstrations, Aug. 19 semiconductor conference.

Evidence: Q2 revenue $80.1M (+287%); 2026 guide $280–290M; adjusted EBITDA loss $120.3M; Aug. 6 close $39.72.

Counterargument: $2.0B pro-forma liquidity, broader commercial mix and 297% RPO growth could justify strategic premium.

Entry / confirmation: watch only; require evidence of narrowing cash burn and profitable revenue mix, or valuation reset.

Invalidation / downside: avoid stance changes on durable margin inflection and milestone verification. Downside includes acquisition integration, dilution and multiple compression.

Principal risks: non-cash GAAP volatility, M&A complexity, technology milestones, government procurement timing.

Technical: $39.72 close within a very wide $25.89–$84.64 52-week range; price alone offers no durable signal.

Confidence

Risk

Opportunity

#5 VKTX · Viking Therapeutics High-risk speculative watch

Nasdaq · approx. $3.9B mid-cap clinical-stage biotech · peptide obesity · binary clinical/dilution risk

Day trade: avoidSwing 1–4 weeks: catalyst watchInvestment: only risk-sized

Thesis / direction: maintenance-dosing data could support differentiation, but no actionable edge exists before timing and full data are known.

Catalyst: VK2735 maintenance data expected Q3; oral Phase 3 initiation expected Q4.

Evidence: VANQUISH 1/2 fully enrolled; $502M cash; prior oral Phase 2 reported up to 80% achieving ≥10% loss at 13 weeks versus 5% placebo.

Counterargument: pre-revenue company facing well-funded incumbents; safety/dropout details, durability and Phase 3 execution matter more than headline efficacy.

Entry / confirmation: require peer-reviewed/full maintenance dataset with tolerability, discontinuations and dose-response; technically, reclaim $34.20 or hold $33.10 after data.

Invalidation / downside: safety imbalance, weak durability, delayed Phase 3 or cash burn acceleration. A failed readout can create a large gap below support.

Biotech checklist: Phase 3 lead program; randomized blinded prior study; current catalyst remains binary; $502M cash but ongoing Phase 3 burn implies future financing risk.

Principal risks: binary data, competition, regulatory path, manufacturing, dilution and liquidity.

Confidence

Risk

Opportunity

Confidence reduced for pending data. Risk dominated by binary readout/competition. Opportunity reflects meaningful differentiation if confirmed.

5 · Changes versus previous report

The injected prior run reported that reliable live data were unavailable and therefore made no verifiable calls. This is the first usable live-researched baseline; no additions/removals or performance comparisons are fabricated.
New paper-tracked classifications: conditional bullish NVDA and LLY; avoid RGTI and IONQ; speculative watch VKTX.
Program remains in the initial paper-tracking phase. Future reports should measure from today's stated closes/conditions, not from hindsight.
Immediate invalidation checkpoint: today's 08:30 ET employment report can change rates, index direction and all short-horizon confidence scores.

6 · Important 7–30 day catalysts

Aug 7 · 08:30 ET — U.S. July Employment Situation

BLS-confirmed. Highest near-term cross-asset catalyst; after this report's cutoff.

Aug 12 · 08:30 ET — U.S. July CPI

BLS-confirmed. Critical for yields and long-duration growth valuations.

Aug 13–14 — PPI / retail-sales window

Calendar cross-check indicates Aug. 13 PPI and Aug. 14 retail sales; verify official calendars immediately before trading.

Aug 19 — IonQ at Needham semiconductor conference

Company-listed; watch integration and commercial comments, not promotional claims alone.

Aug 19 · 14:00 ET — FOMC minutes

Macro-calendar item; rate-path language could move duration assets.

Aug 26 · 14:00 PT — NVIDIA Q2 FY27 results

Company-confirmed. Primary AI catalyst for guidance, supply and data-center demand.

Aug 27 · 13:45 PT — Marvell earnings call

Company IR calendar; networking/custom silicon read-through.

Q3 2026 · date not specified — Viking VK2735 maintenance data

Company guidance, but no exact date. Do not assume a release day.

7 · Bottom line

Current session

No compelling pre-jobs trade. Best setup is to wait 15–30 minutes after 08:30 ET and require yields plus index breadth to confirm. A Nasdaq breakout with stable/falling 10Y favors NVDA; rising yields with failed futures gains argues for cash.

1–4 week swing

NVDA on confirmation, not at any price. Hold $217 / reclaim $223.63 with constructive rates. Biggest risk: hot wages, renewed Hormuz disruption or earnings de-rating.

3–12+ month

LLY has the strongest verified operating momentum; use pullbacks and risk-sized entries. View changes on sustained demand/estimate deterioration, safety or reimbursement shock.

Biggest portfolio risk: the combination of high long yields, oil-driven inflation and crowded mega-cap/biotech expectations. What changes the regime: softer jobs/CPI plus falling 10Y and broad participation would upgrade to risk-on; a hot print, 10Y breakout and oil spike would downgrade to risk-off.

Sources & data quality

Data-quality panel

Market levels cross-checked across CNBC, Markets Insider, CNN Markets and Yahoo historical pages. Quotes are delayed and timestamps differ by venue.
Official Treasury close used for yields; CNBC intraday rates were consistent but not substituted for the official close.
DXY unavailable: accessible pages did not provide a timestamped DXY quote; EUR/USD 1.1529 is shown only as an FX proxy, not an equivalent index.
Direct terminal/curl quote retrieval was blocked by the runtime consent guard; alternative browser, web extraction and search endpoints succeeded. BLS browser navigation was bot-blocked, but its official schedule was retrieved through web extraction/search.
Market cap figures are approximate and venue snapshots can vary with price/share-count timing.